窑Review窑
It has been always difficult to accurately localize tumors in clinical practice. Many imaging techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), and single photon emission computed tomography (SPECT), have been able to grossly localize the majority of tumors, yet it has been quite difficult to precisely confine the exact invasion of tumors. Such uncertainty compromises the ability to radically resect the tumors. Therefore, investigators have sought a target molecule that specifically binds to tumor cells and accurately localizes the range of tumor invasion by detecting the bound target molecule. Chlorotoxin (CTX) has been found to function in such a manner. This peptide is extracted from scorpion venom and is able to specifically bind many tumor cells, which better displays the invasion margins of tumors, and is emerging as a promising technique in diagnostic imaging and targeted therapy for tumors. This article reviews the most recent research advancements.
CTX is a 36amino acid peptide extracted from the venom of Leiurus quinquestriatus and belongs to the scorpion toxinlike superfamily [1] . In nature, CTX is a component of scorpion venom; scorpions paralyze their prey with CTX. The injection of CTX has been reported to paralyze crayfishes and insects. The duration of paralysis varies significantly with the dose of injection in a dosedependent and highly reproducible manner [1, 2] .
CTX is a peptide containing 36 amino acids and 4 disulfide bonds at a relative molecular mass of 3950 u, including 1 tyrosine residue, 8 cysteine residues, and 4 disulfide bonds. The tyrosine residue can be labeled with radioactive iodine and the 8 cysteine residues are conjugated through the 4 disulfide bonds [1] . The amino acid sequence of CTX is listed as follows: MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR [3] . CTX is highly folded by the four disulfide bonds in its structure. Therefore, it has a smaller volume and more condensed molecular structure, readily delivered through the narrow extracellular matrix [4] .
CTX is the first ligand of the chloride ion channel ever reported and with high affinity. Both invitro and invivo studies have demonstrated the blockade of the Cl channel by CTX. Each chloride ion cha nnel can be blocked by only one ligand molecule. DeBin . [2] were the first to study the electrophysiology of CTX and reported that the chloride ion channels on rat colonic epithelial cells were highly sensitive to CTX, which significantly blocked the chloride channels at a minimum concentration of 0.2 mg/mL. Ullrich . [5] demonstrated that the voltagedependent chloride ion currents were present in human acute glioma tissue and CTX decreased the stable chloride currents by 31.4% and the transient chloride currents by 52.1% in orthotopic tissue. Yang .
[6] derived a toxinencoding peptide from Buthus martensii Karsch (BmKCT) in 2005, which was highly homogenous to CTX, and found that the recombinant BmKCT at 600 nmol/L suppressed the chloride currents by (73.53 依 3.21)% on average. Olsen . [7] also reported that out of the large number of chloride ion channels, the Cl channel3 was the most sensitive to CTX.
CTX was initially found to specifically bind to glioma cells rather than normal astrocytes in vitro [8] . Additionally, CTX was found to bind to tumor cells deriving from the neuroectodermal layer rather than normal cells from most organs or tissue [1, 3, 5, 79] . Veiseh .
[10] reported in 2007 that in addition to the neuroectodermalderived tumors, CTX also specifically bound to other matrix metalloproteinase 2 (MMP2)positive tumor cells, including those of primary prostate carcinoma and its lung metastases, and rhabdomyosarcoma.
CTX also inhibits the metastasis and growth of tumor cells. The Transwell study demonstrated that CTX at 5 滋 mol/L inhibited the metastases of U251MG and D54MG glioma cells by more than 60% while in the control group, melanoma cell line SKMEL5, fibroblast cell line Balb3T3, and normal glioma cells were less inhibited. The inhibition of CTX on the metastasis of U251MG cells was dose dependent. In a coculture of glioma cell spheres and murine brain tissue aggregates, the supplementation of 5 滋 mol/L CTX inhibited the invasion in a highly significant manner, while in the glioma cell spheres in the control group invaded the murine brain tissue aggregates in a permeable manner [11] .
In 1998 , Soroceanu .
[8] identified a CTX receptor molecule of 72 ku expressed by human glioma cells, with a molecular mass similar to the chloride ion channel CLC family cloned from muscles and kidneys, and assumed that CTX was able to bind to the chloride ion channels directly. However, further studies demonstrated that CTX bound to the protein complex on cell membranes, which comprised MMP2, 琢 v茁 3 integrin, membrane type 1 matrix metalloprotease (MT1MMP), and tissue inhibitor of matrix metalloproteinase2 (TIMP2). Deshane . [9] performed an affinity extraction of cell membrane patches to verify the true CTX receptors and isolated a protein of 70 ku from the extracts, and subsequently authenticated the extracted protein with mass spectra and sequencing analysis and confirmed its composition of MMP2. The further enzymelinked immunosorbent assay (ELISA) evalu ated the binding properties of CTX with MMP2, demonstrating that the binding ratio of CTX with MMP2 was positively correlated to the concentration of CTX. That is to say, the higher the CTX concentration, the higher the binding ratio. At a concentration of 115 nmol/L, CTX bound MMP at a ratio of 50% and the ratio would approximate 90% at the maximum with increasing concentrations of CTX.
Until recently, all tumors reported to be specifically bound by CTX were positive in MMP 2 [9, 10] . Malignant glioma cells also express MMP1, MMP3, and MMP9 on their cell membranes, while Western blot analysis revealed that only MMP2 could be bound by CTX, justifying that the interactions between CTX and MMP2 were both selective and specific [9] . Veiseh .
[10]
reported in 2007 that the specific binding rate of CTX with tumor cells was positively correlated with the degree of expression of MMP2. However, the pulldown experiment demonstrated that CTX was likely to bind to MMP2 unspecifically and the mechanism of their interaction remains to be investigated [1] .
The binding of CTX with the protein complex results in the intake of the complex and the chloride ion channel ClC3 by cells into the cell membrane lipid rafts, which decreases the number of valid chloride ion channels and thereby suppresses the chloride ion current [9] . CTX almost completely suppresses the chloride ion current, usually in 1015 min. CTX is endocytosed in the process and not readily eliminated though metabolism, which explains why such complexes as 131 ICTX and CTX:Cy5.5 have a longer imaging time in clinical trials [12] .
McFerrin
. studied the metastatic mechanism of glioma cells and identified with both light and electronic microscopy that glioma cells transformed into longer or wedged shapes in the case of their passage through narrow and zigzag extracellular gaps. The 3D imaging quantitative evaluation verified that cells shrunk in volume in the process of the invasion. Cells are known to decrease their volumes by decreasing cytoplasm depending on the intracellular transportation of K + , Cl , and water, in which the chloride ion channel plays a critical role. A higher resting potential is present in glioma cells and the excretion of cytoplasm is likely to be driven by the outflow of Cl [12, 13] . Theoretically, this explains the fact that CTX suppresses metastasis and growth of tumor cells. First, as a chloride ion channel blocker, CTX inhibits the volume shrinkage of tumor cells by blocking the channels, thereby compromising their metastatic capacity. Second, the interactions between CTX and MMP2 also enhance the antiinvasive and antimetastatic capacity of CTX, mainly presenting as the inhibition of CTX on MMP2 activity, degradation in the extracellular matrix and enhanced endocytosis by CTX to decrease the MMP2 expressed on cell membranes [1, 9, 10] . [3, 8, 14] . The characteristic radiation released from these decayed radionuclides have been subsequently detected and recorded by using SPECT and a 酌 camera to accurately qualify, quantify, and localize the CTXlabeled tissues and cells. Such modalities have emerges as a novel imaging diagnostic tools for tumors.
The protocol for the synthesis of such complexes is briefly described as follows. CTX is mixed with sterile sodium phosphate, with concentrations of sodium phosphate at 0.2 mol/L and CTX at 1 mg/mL, and at a pH of 7.6. The admixture is subsequently labeled with radioactive iodine isotope 125 I or 131 I to synthesize the primary product, which is purified with the ionexchange resin column and assayed for its binding rate, radiochemical purity, and pyrogenicity. Shen .
[ ITM601 into the tumor hollow cavity through Ommaya reservoir in patients with recurrent and highly malignant gliomas 2 weeks after tumor resection, aiming to investigate the possibility of 131 ITM601 as an effective tumor imaging tool. On days 03 and days 68, patients received a systematic plane scan of 酌 imaging and a brain SPECT scan. The binding of 131 ITM601 with tumor cells confining the tumor volume displayed on SPECT. MR images, including gadolinium contrast T1weighted and T2weighted images, were also captured after tumor resection. SPECT images and T1/T2weighted images were registered using imaging analysis software, showing that the tumor volume displayed on SPECT images lay between the T1 and T2weighted images, nearing that on the T2weighted images. Theoretically, for the MR images of glioma, the volume reflected by gadolinium contrast T1weighted images would be smaller than the actual volume, which was attributed to the lack of neoangiogenesis in invasive tumor cells at the peripheries of tumor parenchymas. However, the volume reflected by the T2weighted images was larger than the actual volume because the highintensity signals were likely to reflect the nontumorous factors, such as angioedema or cytotoxicity. Therefore, as a contrast medium, 131 ITM601 in SPECT reflected the more accurate tumor volume than MRI, verifying the binding of 131 ITM601 with the invasive tumor cells at the peripheries of the tumor parenchymas. Such an approach is still defective with the low resolution of SPECT, making it very difficult to evaluate the actual range of the local tumor.
The same team also studied the possibility using intravenous injection for tumor imaging and thereby included any systemderived patients with cancer. The expected results will demonstrate that the specific uptake and binding of 131 ITM601 by tumor cells could be observed on systematic imaging.
131
ITM601 can be used as a contrast medium for multiple tumors and the therapeutic agent for prospective targeted therapy in such cases [14, 15] .
Mamelak .
[1] injected a single dose of 131 ITM601 at 37 MBq into the hollow cavity of tumors through Ommaya reservoir in patients with recurrent and highly malignant gliomas 2 weeks after tumor resection, aiming to observe its biologic distribution and safety profile in vivo. The study revealed that the radioactive dose systematically received was 0.11 nGy/Bq, ranging from 0.050.19 nGy/Bq, while normal organs, including the stomach, kidneys, and thyroid gland, received minimal radioactive doses in a clinically nonsignificant manner. In contrast, the area within 2 cm of the tumor cavity walls received a radioactive dose at 3.2474.32 nGy/Bq and 21.89 nGy/Bq on average, significantly higher than other tissue and organs. The halfelimination life of 131 ITM601 around the tumor cavity wall was 69 h on average, while for 131 ITM601 in such tissue and organs as the stomach, kidneys, and bone marrow, were all less than 30 h. The 酌 imaging showed that 131 ITM601 was concentrated in the cavity and the periphery over 5 successive days, suggesting its prolonged retention around the tumor cavity.
All patients on trial tolerated 131 ITM601 well, and none reported any discomfort. Neither gradeIII nor IV toxicity were observed in the short term. However, in the 22 day observation period after administration, 3 patients developed more serious adverse effects, likely to be associated with administration. Their symptoms consisted of high fever, chills, abnormal sensation of the upper limbs, mild brain edema on CT scan, progressive paralysis of the left limbs, infection in the tumor cavity, and osteomyelitis. Another 2 patients developed administration associated symptoms after 22 days. One patient developed tonicclonic seizures and another patient developed headache, atony of facial expression muscles, impaired hearing, and compromised balance. The group has started further research to characterize the safety profile of the highdose intracavitary injection of TM601, which has yet to be published [1, 14, 15] .
The complexes of CTX with other molecules have played more and more critical roles in diagnostic imaging and treatment of tumors, whose development is encouraging and promising. The University of Washington and the Fred Hutchinson Cancer Research Center are the leading institutions in the field worldwide. The major results published jointly by investigators at the two institutions are described as follows.
The study group conjugated CTX to fluorescent material Cy5.5 in 2007 to produce the complex of CTX:Cy5.5. Optical waves released from CTX:Cy5.5 are near the infrared spectrum and can be used for optical imaging. The specific binding of CTX:Cy5.5 with tumor cells can be detected with light microscopy. First, a glioma mouse model was established and 0.1 mL of 20 滋 mol/L CTX:Cy5.5 was subsequently injected through the tail vein. A small animal in vivo imaging system (Xenogen IVIS100 system) was used to observe for 14 successive days, which identified continuously and significantly increased signals in the tumor cell area compared to normal tissue. On dorsal plane images, higherintensity signals were detected in the gallbladder area due to concentrated probes, while no other signals were detectable except for those from the binding area of CTX:Cy5.5 with tumor cells. However, if the unlabeled CTX and CTX:Cy5.5 were concurrently injected, imaging of the tumor area would be blocked, since CTX and CTX:Cy5.5 competed against each other for the binding sites with tumor cells. Hundreds of tumor cell metastatic sites were identified in the lymphatic space of the mice, attributable to the higher sensitivity of the optical imaging (500fold of that for MRI). Intravenous injection of CTX:Cy5.5 did not cause any neurologic or behavioral defects in the mice and no difference in the control group was detected by histopathologic examination on autopsy. Therefore, intravenous injection of CTX:Cy5.5 at the optical imaging dose was not toxic to mice. The high sensitivity of optical imaging encourages both surgeons and patients because the complex detected almost all the tumor cells for the purpose of resection and cancer sites could be differentiated from surrounding normal cells with intraoperative infrared microscopy [10] .
In 2008, the study group developed CTXsuper paramagnetic nanoprobes, including iron oxide nanoparticles (NPs) coated with polyethylene glycol (PEG) and CTX. The nanoparticles could bind to glioma cells specifically and could be used as a contrast medium for MRI to enhance the differentiation of the tumor from normal brain tissue. In contrast to the traditional gadolinium chelate, the nanoparticles had a prolonged imaging time in displaying the tumor margins because the probes were more endocytosed but more slowly eliminated. Recently, the study group also reported that the nanoparticles significantly suppressed the invasion of tumor cells and multiple surface MMP2postive tumors were likely to respond to the nanoparticles. The histologic pathology did not detect any acute toxicity or adverse effect [16] .
In August 2009, the study group published their most recent product, a dual modality optical/MR imaging nanoprobe. Iron oxide nanoparticles (NPs) were the probe core, which was coated with biocompatible polyethylene glycol (PEG)chitosan in the form of nanoparticle copolymer covalently conjugated with CTX and Cy5.5. The probe could label the tumor cells in genetically engineered mice and be dually detected by optical imaging and MRI, which proved to be nontoxic, permeable through the bloodbrain barrier, and able to bind to tumor cells for a long time. Therefore, the nanoprobe is expected to be used for prospective diagnosis and treatment in various human tumors [17] .
In 2009, the study group reported a nonviral nanovector system PPEGAFCTX comprising a polyethylenimine (PEI) polymer, polyethylene glycol (PEG), fluorescent dye Alexa Fluor 647 (AF), and CTX, which could be used to bind a series of tumor cells specifically for genetic treatment. The nanovector could be effectively loaded with genes for the specific labeling and genetic transfection of tumor cells.
Gene therapy is faced with many problems, such as its unfavorable safety profile, poor vectorbinding specificity, and low transfection rate. As a gene vector, the PEI polymer is anticipated due to its highly efficient transfection, which is less than ideal considering its intimate toxicity and nonspecific binding. The PPEGAFCTX vector developed by the study group was covalently conjugated with PEG to improve the biocompatibility of PEI and decrease the potential toxicity to healthy cells. Additionally, the binding with CTX endowed the vector the specific binding with tumor cells, which also decreased its toxicity to healthy cells. The invitro study demonstrated that the vector enabled the positive genetic transfection at various concentrations. In glioma cell line C6 and myeloblastoma cell line DAYO, the nanovector justified its higher binding specificity and genetic transfection rate. As a binding ligand, CTX enables the nanovector to treat more types of tumors genetically. At present, it has rarely been documented that the vector is toxic, preliminarily confirming that the vector is a safe, effective, and specific tool [18] .
CTX has emerged as a new platform for diagnostic imaging and treatment of tumors, with some major benefits: (1) its smaller and condensed structure; (2) the feasibility of artificial synthesis and the readily modified chemical structure with a tyrosine residue conjugating iodine or other molecules covalently; (3) its ability to penetrate the bloodbrain barrier and more readily diffuse into tumor parenchymas; (4) it is not readily eliminated through the metabolism with a longer imaging time due to intracellular binding with tumor cells; (5) its derivation from an invertebrate, being not rejected by human tissue, the absence of intimate toxicity without binding to normal tissue and cells; and (6) its antitumor activity in inhibiting tumor invasion and metastasis [1] . Whether CTX specifically binds to tumor cells from other human systems, especially those from MMP2 positive tumors, remains to be verified. Localizing tumor cells with CTX, despite that specifically binds tumor cells, is still difficult. Currently, investigators have conjugated CTX with radioactive iodine isotopes, fluorescent molecules, and nanoparticles, and subsequently localized these conjugants with the imaging tools. However, most tools for localization are defective or complex, and developing a simple and effective localizing method continues to be extensively studied. Additionally, the hazards of various complexes in vivo should be monitored in the long term. The further study on CTX and the development of its complexes will make it promising for CTX to become a novel modality for diagnosis and targeted therapies for tumor.
